Alphatec (NASDAQ:ATEC) Stock Dropped to Market Perform by BMO Capital Markets

BMO Capital Markets lowered shares of Alphatec (NASDAQ:ATEC) from an outperform rating to a market perform rating in a research note released on Friday morning, MarketBeat reports. The firm currently has $8.00 price target on the medical technology company’s stock.

ATEC has been the topic of several other reports. TD Cowen reduced their price target on Alphatec from $13.00 to $10.00 and set a “buy” rating on the stock in a report on Friday. Wall Street Zen downgraded Alphatec from a “buy” rating to a “hold” rating in a research note on Sunday, October 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alphatec in a report on Monday, August 3rd. Needham & Company LLC cut their target price on shares of Alphatec from $14.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday. Finally, Stifel Nicolaus cut their target price on shares of Alphatec from $16.00 to $13.00 and set a “buy” rating on the stock in a research report on Wednesday, July 8th. Twelve analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $16.60.

Alphatec Stock Down 38.1%

NASDAQ ATEC opened at $7.04 on Friday. The company has a market cap of $1.09 billion, a price-to-earnings ratio of -12.80 and a beta of 0.78. Alphatec has a twelve month low of $6.81 and a twelve month high of $23.29. The business’s fifty day moving average is $10.14 and its 200 day moving average is $10.62.

Alphatec (NASDAQ:ATEC) last issued its earnings results on Thursday, October 29th. The medical technology company reported $0.09 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.01). The firm had revenue of $221.17 million during the quarter, compared to analyst estimates of $225.16 million. Alphatec had a negative return on equity of 6,752.24% and a negative net margin of 10.35%. Alphatec’s revenue for the quarter was up 12.6% on a year-over-year basis. During the same period in the previous year, the company earned $0.03 EPS. On average, research analysts anticipate that Alphatec will post -0.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Patrick Miles bought 115,000 shares of the company’s stock in a transaction that occurred on Thursday, September 10th. The shares were acquired at an average price of $8.81 per share, for a total transaction of $1,013,150.00. Following the completion of the acquisition, the chief executive officer directly owned 5,893,551 shares in the company, valued at approximately $51,922,184.31. This represents a 1.99% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, General Counsel Tyson Marshall sold 8,168 shares of the business’s stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $9.65, for a total transaction of $78,821.20. Following the completion of the transaction, the general counsel owned 630,398 shares in the company, valued at approximately $6,083,340.70. The trade was a 1.28% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 13.48% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. State of Wyoming boosted its position in shares of Alphatec by 87.7% during the 3rd quarter. State of Wyoming now owns 30,666 shares of the medical technology company’s stock valued at $316,000 after purchasing an additional 14,328 shares in the last quarter. Sterling Capital Management LLC grew its stake in Alphatec by 841.5% during the third quarter. Sterling Capital Management LLC now owns 4,105 shares of the medical technology company’s stock worth $42,000 after purchasing an additional 3,669 shares during the period. Kopp Family Office LLC grew its stake in Alphatec by 0.4% during the third quarter. Kopp Family Office LLC now owns 330,266 shares of the medical technology company’s stock worth $3,408,000 after purchasing an additional 1,303 shares during the period. AA Financial Advisors LLC grew its stake in Alphatec by 140.5% during the third quarter. AA Financial Advisors LLC now owns 48,094 shares of the medical technology company’s stock worth $496,000 after purchasing an additional 28,094 shares during the period. Finally, Congress Asset Management Co. increased its holdings in Alphatec by 20.7% in the third quarter. Congress Asset Management Co. now owns 532,069 shares of the medical technology company’s stock worth $5,491,000 after purchasing an additional 91,431 shares in the last quarter. 66.35% of the stock is owned by institutional investors and hedge funds.

Alphatec News Roundup

Here are the key news stories impacting Alphatec this week:

• Positive Sentiment: Third-quarter revenue increased 12.6% year over year to approximately $221.2 million, while earnings of $0.09 per share improved from $0.03 a year earlier. Management continues to target a 16% adjusted EBITDA margin for 2026. Alphatec third-quarter results
• Positive Sentiment: Wells Fargo lowered its price target from $14 to $12 but maintained an “overweight” rating, implying substantial potential upside if Alphatec stabilizes growth and executes on its profitability plans. Wells Fargo rating
• Neutral Sentiment: Analyst expectations remain divided: BMO Capital Markets downgraded the stock to “market perform” with an $8 price target, while other analysts continue to see valuation upside. BMO Capital Markets rating
• Negative Sentiment: Alphatec reduced its 2026 revenue outlook to approximately $862 million from roughly $882 million, below the prior market expectation. Management cited fewer surgeons purchasing its bone-graft products used in spinal-fusion procedures. Alphatec guidance reduction
• Negative Sentiment: Third-quarter adjusted earnings of $0.09 per share and revenue of $221.2 million both missed analyst estimates, reinforcing concerns about slowing demand despite year-over-year growth. Alphatec earnings miss
• Negative Sentiment: Levi & Korsinsky and Ademi LLP announced investigations into potential securities-law violations related to Alphatec’s outlook and subsequent decline. These notices may add reputational and legal risk, although they do not establish wrongdoing. Alphatec investor investigation

Alphatec Company Profile

Alphatec Holdings, Inc is a medical technology company focused on the design, development and commercialization of products and procedural solutions for spine surgery. The company aims to improve the treatment of spinal disorders through technologies that support spinal fusion, deformity correction, reconstruction and minimally invasive procedures.

Its portfolio includes spinal implants, surgical instruments, navigation and imaging technologies, and intraoperative monitoring solutions.